52 unknown, 45 recruiting, 42 completed, 27 terminated. 211 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 211 | Unknown 52, Recruiting 45, Completed 42, Terminated 27, Not yet recruiting 23, Active not recruiting 11, Withdrawn 7, Suspended 4 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution APR-TD011 (RLF-TD011) - Cutaneous T Cell Lymphoma | Early Phase 1 | Not yet recruiting | Northwestern University | 30 | 2027-01-01 | 2026-05-01 |
| SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia SNC116 - B-cell Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Shanghai Simnova Biotechnology Co.,Ltd. | 28 | 2026-09-01 | 2026-09-21 |
| Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia PID23 Injection - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Zhujiang Hospital | 18 | 2026-08-01 | 2026-07-10 |
| Evaluate Advanced Pneumatic Compression Device With Revised Compression Programming for Lymphedema Treatment Advanced pneumatic compression device (APCD), Advanced pneumatic compression device (APCD) with revised compression programming, Indocyanine Green (IC-Green) - Lower Extremity Lymphedema | Early Phase 1 | Recruiting | Tactile Medical | 5 | 2026-07-09 | 2026-08-11 |
| GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma GoFast CD19 CAR T Cells - Relapsed or Refractory Large B-cell Lymphoma | Early Phase 1 | Not yet recruiting | Chinese PLA General Hospital | 9 | 2026-06-30 | 2026-06-26 |
| CAR-T Cell Therapy for ALL CAR-T cell infusion - Relapsed Acute Lymphoblastic Leukemia (ALL) | Early Phase 1 | Recruiting | Dr. Zaineb Akram | 10 | 2026-06-01 | 2026-07-10 |
| A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy humanized CD19 CAR-T Cells with TLR2 - B Lymphoblastic Leukemia/Lymphoma | Early Phase 1 | Not yet recruiting | Zhujiang Hospital | 60 | 2026-06-01 | 2026-01-12 |
| A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder) - ARDS (Moderate or Severe), ARDS (Acute Respiratory Distress Syndrome) | Early Phase 1 | Recruiting | Shanghai Zhongshan Hospital | 24 | 2026-05-14 | 2026-06-11 |
| RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas RN1701 injection - Relapsed/Refractory B-cell Lymphoma | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 10 | 2026-05-08 | 2026-05-04 |
| Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors Methionine-Reduced Diet - Adenocarcinoma, Basal Cell Carcinoma | Early Phase 1 | Recruiting | University of California, Irvine | 25 | 2026-05-01 | 2026-07-31 |
| Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine EBV mRNA vaccine - HIV Associated Lymphoma | Early Phase 1 | Not yet recruiting | West China Hospital | 6 | 2026-05-01 | 2026-05-01 |
| Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma CD19/CD20 Tandem Dual CAR-T - Relapsed/Refractory B-Cell Lymphoma | Early Phase 1 | Not yet recruiting | Affiliated Hospital to Academy of Military Medical Sciences | 20 | 2026-04-30 | 2026-04-29 |
| A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma CT1182 injection - B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2026-04-30 | 2026-04-23 |
| Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma GI001 Injection - B-Cell Non-Hodgkin Lymphoma | Early Phase 1 | Not yet recruiting | Ruijin Hospital | 9 | 2026-04-20 | 2026-05-13 |
| CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation CAR19BCMA-T cells, fludarabine and cyclophosphamide - Relapsed or Refractory Plasma Cell Neoplasms, Lymphomas/Leukemias With Plasmacytic Differentiation | Early Phase 1 | Not yet recruiting | Affiliated Hospital to Academy of Military Medical Sciences | 20 | 2026-04-02 | 2026-04-08 |
| Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL CD7 CAR-T cell intravenous infusion - T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-03-15 | 2026-03-17 |
| Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib Pirtobrutinib - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Early Phase 1 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 30 | 2026-03-11 | 2026-10-22 |
| CD30 CAR-T in the Treatment of CD30 Positive Lymphoma chimeric antigen receptor gene modified T cells - Lymphoma, B Cell Lymphoma | Early Phase 1 | Suspended | Shandong Qilu Cell Therapy Engineering Technology Co., Ltd | 15 | 2026-03-01 | 2026-09-28 |
| Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia SYNCAR-100 Injection - B-Cell Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | Zhejiang University | 16 | 2026-02-28 | 2026-02-24 |
| A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) DT-7012 - Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides | Early Phase 1 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-01-01 | 2025-10-09 |
Showing 20 of 211. Sign in to see all of them.
Lymphoma (41) · Lymphoma, B-Cell (37) · Lymphoma, Non-Hodgkin (37) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (36) · Burkitt Lymphoma (29) · Lymphoma, Large B-Cell, Diffuse (21) · Lymphoma, Follicular (19) · Leukemia, Lymphocytic, Chronic, B-Cell (16) · Lymphoma, Mantle-Cell (15) · Recurrence (15) · Leukemia (13) · Hodgkin Disease (12) · Multiple Myeloma (12) · Leukemia, Myeloid, Acute (11) · Lymphoma, T-Cell (9)
Hemic and Lymphatic Diseases (211) · Immune System Diseases (201) · Lymphoproliferative Disorders (198) · Neoplasms by Histologic Type (196) · Immunoproliferative Disorders (195) · Neoplasms (193) · Lymphoma (125) · Lymphoma, Non-Hodgkin (96) · Hematologic Diseases (79) · Leukemia (59) · Leukemia, Lymphoid (58) · Lymphoma, B-Cell (43) · DNA Virus Infections (32) · Herpesviridae Infections (32)
Cyclophosphamide (19) · Rituximab (10) · fludarabine (10) · Etoposide (6) · Vincristine (6) · Doxorubicin (5) · 68Ga-pentixafor (4) · Dexamethasone (4) · Filgrastim (4) · Granulocyte Colony-Stimulating Factor (4) · Immunotherapy, Adoptive (4) · Magnetic Resonance Spectroscopy (4) · Methotrexate (4) · Prednisone (4) · Radiotherapy (4)
Zhejiang University (12) · Memorial Sloan Kettering Cancer Center (7) · He Huang (5) · M.D. Anderson Cancer Center (5) · Mayo Clinic (5) · Northwestern University (5) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (4) · Allife Medical Science and Technology Co., Ltd. (4) · Anhui Provincial Hospital (4) · Hebei Yanda Ludaopei Hospital (4) · Institute of Hematology & Blood Diseases Hospital, China (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Washington University School of Medicine (4) · City of Hope Medical Center (3) · Peking Union Medical College Hospital (3)
China (89) · United States (88) · Australia (2) · Denmark (2) · Austria (1) · Canada (1) · Czechia (1) · France (1) · Indonesia (1) · Pakistan (1) · Spain (1) · Sweden (1)
He Huang, MD (3) · Ariela Noy, MD (2) · Fang Liu, MD, PhD (2) · Farrokh Dehdashti, M.D. (2) · Hai Yi, M.D. & Ph.D. (2) · Hongyu Zhang, MD, PhD (2) · Jeffrey J. Raizer, MD (2) · Jianmin Luo, PhD&MD (2) · Lubomir Sokol, MD, PhD (2) · Qingming Wang, M.D. (2) · Sunil Abhyankar, MD (2) · Xi Zhang, MD (2) · Yi Yao, ph.D (2) · Aaron Mangold (1)
PMID 40540129, PMID 18042692, PMID 19880495, PMID 20671118, PMID 23023715, PMID 23649469, PMID 24142051, PMID 26202875, PMID 26222726, PMID 26353084, PMID 26424652, PMID 27269947, PMID 28911074, PMID 29272362, PMID 29652233, PMID 29920566, PMID 29925499, PMID 30256977, PMID 30846271, PMID 31776631, PMID 32298202, PMID 32840736, PMID 33242451, PMID 33851477, PMID 34177581, PMID 34344873, PMID 34435552, PMID 34651291, PMID 35349631, PMID 35468680, PMID 35973200, PMID 36189306, PMID 36719647, PMID 36808074, PMID 36923556, PMID 37077913, PMID 37093350, PMID 37192741, PMID 37781191, PMID 38143760, PMID 38592213, PMID 39563035, PMID 39887860, PMID 40129522, PMID 40311885, PMID 40406106, PMID 40574863, PMID 40940923, PMID 41110448, PMID 41194247
P30CA033572 (3), P30CA015083 (2), P30CA043703 (2), 2019 (1), K12CA090433 (1), P01CA068484 (1), P30CA006516 (1), P30CA006973 (1), P30CA036727 (1), P30CA060553 (1), P30CA072720 (1), P30CA138292 (1), P50CA097274 (1), R01CA277493 (1), R01HL140898 (1)